429 related articles for article (PubMed ID: 15731414)
1. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
2. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
3. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
4. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
5. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
6. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
7. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
8. Tailoring arthritis therapy in the wake of the NSAID crisis.
Olsen NJ
N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
[No Abstract] [Full Text] [Related]
9. The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain.
Reuben SS
Acta Anaesthesiol Scand; 2005 Mar; 49(3):424; author reply 425. PubMed ID: 15752415
[No Abstract] [Full Text] [Related]
10. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Epstein RA
Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
[No Abstract] [Full Text] [Related]
11. FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs.
FDA Consum; 2005; 39(3):7. PubMed ID: 16127812
[No Abstract] [Full Text] [Related]
12. Celecoxib shown effective in preventing colon polyps.
Nelson NJ
J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
[No Abstract] [Full Text] [Related]
13. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
14. Coxibs and cardiovascular disease.
Fitzgerald GA
N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
[No Abstract] [Full Text] [Related]
15. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
16. Merck withdraws Vioxx; FDA issues public health advisory.
FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
[No Abstract] [Full Text] [Related]
17. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
18. Arthritis medicines and cardiovascular events--"house of coxibs".
Topol EJ
JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
[No Abstract] [Full Text] [Related]
19. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Vanchieri C
J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
[No Abstract] [Full Text] [Related]
20. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
[Next] [New Search]
